Effects of Pretreatment with Different Doses of Lidocaine on Injection Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

210 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

One of the medications administered to patients in general anesthesia practice is rocuronium, which causes pain during intravenous administration. It is known that a drug containing lidocaine as the active ingredient can reduce the pain caused by rocuronium in different doses. The effective dose of lidocaine remains a topic of debate. In our study, we aimed to investigate the efficacy of two different doses of lidocaine. No adverse effects are expected from this medication.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Usefulness of Lidocaine in Oral and Maxillofacial Surgeries Under General Anesthesia for Pain Control After Operation

NCT03479320

Pain, Postoperative

COMPLETED PHASE4

Reduction of Rocuronium-induced Injection Pain With Aspiration of Blood

NCT06150001

Anesthesia, General

COMPLETED NA

Effect of Ketamine Addition to Lidocaine in Rhinoplasty

NCT01827020

Nose Deformities, Acquired

COMPLETED PHASE4

Lidocaine Spray Use on Patients Comfort in Undergoing Bladder Catheterization

NCT06585748

Urinary Catheterization As the Cause of Abnormal Reaction of Patient, or of Later Complication, Without Mention of Misadventure At Time of Procedure

RECRUITING

The Influence of Intravenous Lidocaine on the Action of the Neuromuscular Blocker Rocuronium

NCT00828373

Neuromuscular Block

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The patients were randomly divided into three groups by a simple drawing-lots method: control group (Group C), 40 mg lidocaine group (Group L) and 1 mg/kg lidocaine group (Group L1). All patients were taken to the operating room without premedication and standard monitoring was applied. A 20 G intravenous catheter was inserted on the dorsum of the patients' non-dominant hand, and 100 ml/hour of physiological saline solution was infused over a 5-minute period. After randomization, 5 ml of isotonic solution was administered to the control group, 40 mg of lidocaine to the L group, and 1 mg kg-1 of lidocaine intravenously to the L1 group. Patients were administered 0.06 mg/kg of rocuronium, and they were asked, "Do you feel any pain or discomfort in your arm?" The pain intensity expressed by the patient was evaluated and recorded using the 5-point pain scale. After induction and intubation, the patients' blood pressure, pulse, and saturation values were recorded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rocuronium Adverse Reaction Lidocaine Adverse Reaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Injection of serum physiologic that contains no drug.

We injected serum physiologic that contains no drug before injection of rocuronium and recorded pain score.

Group Type PLACEBO_COMPARATOR

serum physiologic

Intervention Type DRUG

We injected serum physiologic before rocuronium injection. Then we recorded pain score by using visual analog scale.

40 mg lidocain group

We injected 40 mg lidocain for the prevention of injection pain caused by rocuronium. We injected 0.06 mg/kg rocurunium and recorded pain by using visual analog scale.

Group Type EXPERIMENTAL

Lidocain 40 mg

Intervention Type DRUG

We injected 40 mg lidocain before rocuronium injection. Then we recorded pain score by using visual analog scale.

1 mg/kg lidocain group

We injected 1 mg/kg lidocain for the prevention of injection pain caused by rocuronium. We injected 0.06 mg/kg rocurunium and recorded pain score by using visual analog scale.

Group Type EXPERIMENTAL

lidocain 1 mg/kg

Intervention Type DRUG

We injected 1 mg/kg lidocain before rocuronium injection. Then we recorded pain score by using visual analog scale.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lidocain 40 mg

We injected 40 mg lidocain before rocuronium injection. Then we recorded pain score by using visual analog scale.

Intervention Type DRUG

lidocain 1 mg/kg

We injected 1 mg/kg lidocain before rocuronium injection. Then we recorded pain score by using visual analog scale.

Intervention Type DRUG

serum physiologic

We injected serum physiologic before rocuronium injection. Then we recorded pain score by using visual analog scale.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lidocain 40 mg lidocain lidocain 1 mg/kg lidocain izotonic fluid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients aged between 18 and 65 with ASA I and II

Exclusion Criteria

* Chronic sedative anxiolytic use
* Those with ASA III and higher
* Patients under 18 and over 65 years of age
* Those with severe COPD, asthma, or reactive airway disease
* Patients with a history of neuropsychiatric or neurological diseases
* Those with infections on the back of the hand
* Pregnant women
* Patients who will undergo rapid induction
* Patients with liver and kidney dysfunction
* Those with a history of thrombophlebitis
* Patients with muscle diseases

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes